BENICAR HCT
LOE Approachingolmesartan medoxomil-hydrochlorothiazide
NDAORALTABLET
Approved
Jun 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
BENICAR HCT (olmesartan medoxomil-hydrochlorothiazide) is (ace, kininase ii). First approved in 2003.
Drug data last refreshed 7m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BENICAR HCT is a fixed-dose combination of olmesartan medoxomil (an angiotensin II receptor blocker) and hydrochlorothiazide (a thiazide diuretic) for oral treatment of hypertension. Olmesartan selectively blocks AT1 receptors to inhibit vasoconstriction and aldosterone release, while HCTZ reduces plasma volume through diuretic action. The combination leverages complementary mechanisms to achieve additive blood pressure reduction.
$0.007BPart D
LOE ApproachingDeclining
Product is transitioning toward loss of exclusivity with modest Part D utilization, indicating a contracting team focused on retention rather than growth initiatives.
Mechanism of Action
(ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation and renal reabsorption of sodium. Olmesartan blocks the vasoconstrictor effects of…
Pharmacologic Class:
Thiazide Diuretic
Indications
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.